CAR039 Comprehensive Lipid Profile Testing in the Evaluation of ...
CAR039 Comprehensive Lipid Profile Testing in the Evaluation of ...
CAR039 Comprehensive Lipid Profile Testing in the Evaluation of ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Davidson, M.H., Corson, M.A., Alberts, M.J., Anderson, J.L., Gorelick, P.B., Jones, P.H., & et al.<br />
(2008). Consensus panel recommendation for <strong>in</strong>corporat<strong>in</strong>g lipoprote<strong>in</strong>-associated phospholipase A2<br />
test<strong>in</strong>g <strong>in</strong>to cardiovascular disease risk assessment guidel<strong>in</strong>es. American Journal <strong>of</strong> Cardiology, 1010,<br />
12, S51F–57F.<br />
Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guidel<strong>in</strong>e for assessment <strong>of</strong> cardiovascular<br />
risk <strong>in</strong> asymptomatic adults: a report <strong>of</strong> <strong>the</strong> American College <strong>of</strong> Cardiology Foundation/American<br />
Heart Association Task Force on Practice Guidel<strong>in</strong>es. J Am Coll Cardiol 2010;56:e50-e103.<br />
The Lp-PLA2 Studies Collaboration: Lipoprote<strong>in</strong>-associated phospholipase A2 and risk <strong>of</strong> coronary<br />
disease, stroke, and<br />
mortality: collaborative analysis <strong>of</strong> 32 prospective studies. Lancet 2010; 375: 1536–44.<br />
A<strong>the</strong>rotech Website, http://www.<strong>the</strong>vaptest.com Accessed March 2012<br />
Maki KC, Dickl<strong>in</strong> MR, Davidson MH, Mize PD, Kulkarni KR. Indicators <strong>of</strong> <strong>the</strong> A<strong>the</strong>rogenic<br />
Lipoprote<strong>in</strong> Phenotype Measured with Density Gradient Ultracentrifugation Predict Changes <strong>in</strong><br />
Carotid Intima-Media Thickness <strong>in</strong> Men and Women. January 2012 Volume 2012:8 Pages 31 – 38<br />
Mora S, Szklo M, Otvos J, Greenland P, Psaty BM, G<strong>of</strong>f DC Jr, O'Leary DH, Saad MF, Tsai MY,<br />
Sharrett AR: LDL particle subclasses, LDL particle size, and carotid a<strong>the</strong>rosclerosis <strong>in</strong> <strong>the</strong> Multi-Ethnic<br />
Study <strong>of</strong> A<strong>the</strong>rosclerosis (MESA) A<strong>the</strong>rosclerosis 192:211–217, 2007<br />
Rob<strong>in</strong>s SJ, Coll<strong>in</strong>s D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, McNamara JR,<br />
Kashyap ML, Hershman JM, Wexler LF, Rub<strong>in</strong>s HB; VA-HIT Study Group. Veterans Affairs High-<br />
Density Lipoprote<strong>in</strong> Intervention Trial. Relation <strong>of</strong> gemfibrozil treatment and lipid levels with major<br />
coronary events: VA-HIT: a randomized controlled trial. JAMA 285:1585–1591, 2001<br />
Cromwell WC, Otvos JD: Low-density lipoprote<strong>in</strong> particle number and risk for cardiovascular disease.<br />
Curr A<strong>the</strong>roscler Rep 6:381–387, 2004<br />
PROTOCOL HISTORY/REVISION INFORMATION<br />
Date<br />
03/22/2012<br />
12/23/2010<br />
Action/Description<br />
Corporate Medical Affairs Committee<br />
<strong>Comprehensive</strong> <strong>Lipid</strong> <strong>Pr<strong>of</strong>ile</strong> <strong>Test<strong>in</strong>g</strong> <strong>in</strong> <strong>the</strong> <strong>Evaluation</strong> <strong>of</strong> Cardiovascular Disease Page 14 <strong>of</strong> 14
Change language